Drug Detail

Information about SF1126

Generic Name
IND	SF1126
Brand Name (US)
Manufacturer	Semafore
Drug Type	Congugate, prodrug
Delivery	Intravenous
Approval Status	Phase 1
Indications
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block KIT Signal Path
Drug Category	PI3K inhibitor

Semafore Pharmaceuticals, a small company in Indianapolis, Ind. has developed a broad spectrum PI3K inhibitor based on the lab drug LY294002. SF1126 is a Prodrug that inhibits Class IA PI3Ks and DNA-PK and mTOR. A Prodrug is given in one form and converted into a different, active form by metabolic action in the body. Semafore has designed SF1126 to have an affinity for the vascular forming areas of tumors.

1/12/2012 "Semafore Pharmaceuticals (Indianapolis, IN) a drug discovery and development company focused on small molecule modulators of the PI3 Kinase (PI3K) & PTEN cell signaling pathway has raised $9.5M in Series B funding led by Twilight Venture Partners."